Clinical Trial Update: Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating nonmyeloablative allogeneic stem cell transplantation for various hematologic disorders has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Chronic Lymphocytic Leukemia
• Chronic Myeloid Leukemia
• Hodgkin Lymphoma
• Multiple Myeloma
• Myelodysplastic Syndromes
• Non-hodgkin Lymphoma

Snippet

Sponsor: Beth Israel Deaconess Medical Center | Conditions: AML, ALL | Phase 2 | Status: COMPLETED